Share Prices & Company Research

Stockbroking

BTG

Current Price 679.54p Bid 679.50p Ask 680.00p Change 0.29%
Last Updated: 18/02/2018 02:38. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

BTG plc is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. It has a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges.

Financial Highlights Year Ended 31/03/2017

Turnover
£570.50m
Operating Profit
£57.50m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
77.07

Key Personnel

Dr Pamela Louise Makin
Chief Executive Officer
Duncan Kennedy
Chief Financial Officer
Garry Watts
Non-Executive Chairman
Dr Susan Elizabeth Foden
Non-Executive Director
Giles Francis Bertram Kerr
Non-Executive Director
Ian Fraser Robert Much
Non-Executive Director
William James O`Shea
Non-Executive Director
Richard Leslie Martin Wohanka
Non-Executive Director
Gregory Ackley Barrett
Non-Executive Director
Graham Charles Hetherington
Non-Executive Director

Stock Details

EPIC
BTG
ISIN
GB0001001592
Shares in Issue
386,465,126
Market cap
£2,591.25m

Analyst Views (4)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
680.00p
Bid Price
679.50p
Ask Price
680.00p
Volume
382504
Change Today
2.00p
% Change Today
0.29%
Open
683.00p
Previous Close
680.00p
Intraday High
686.03p
Intraday Low
677.00p
52 Week High
784.00p
52 Week Low
546.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

BTG Intra-day Chart

BTG News

News in this section is provided by MoneyAM

BTG holds interventional medicine seminar 07 Dec 2017 | 08:00 BTG strengthens its board 27 Nov 2017 | 09:20 Broker Forecast - JP Morgan Cazenove issues a broker note on BTG PLC 22 Nov 2017 | 10:40 BTG reiterates guidance after strong H1 14 Nov 2017 | 07:41 Uplift in utilities fails to boost FTSE 06 Nov 2017 | 16:54 FTSE slips on weaker financial stocks 06 Nov 2017 | 11:57 BTG to take £53.5m hit from Wellstat ruling 06 Nov 2017 | 07:52 BTG acquires Roxwood; reiterates sales guidance 05 Oct 2017 | 08:15 BTG ordered to pay $55.8m damages 20 Sep 2017 | 09:33 Director Deals - BTG PLC (BTG) 01 Sep 2017 | 15:05 Study demonstrates efficacy of EKOS therapy, says BTG 16 Jun 2017 | 08:17 FLASH: EKOS therapy meets endpoint in study, says BTG 16 Jun 2017 | 07:14 BTG confirms date of AGM 13 Jun 2017 | 14:26 Director Deals - BTG PLC (BTG) 12 Jun 2017 | 15:45 Director Deals - BTG PLC (BTG) 12 Jun 2017 | 15:45 Director Deals - BTG PLC (BTG) 12 Jun 2017 | 15:40 Director Deals - BTG PLC (BTG) 12 Jun 2017 | 15:40 BTG unveils results of OPTALYSE PE study 22 May 2017 | 13:03 Broker Forecast - Panmure Gordon issues a broker note on BTG PLC 19 May 2017 | 12:10 Broker Forecast - Peel Hunt issues a broker note on BTG PLC 17 May 2017 | 12:10 Broker Forecast - JP Morgan Cazenove issues a broker note on BTG PLC 17 May 2017 | 09:30 Broker Forecast - Panmure Gordon issues a broker note on BTG PLC 16 May 2017 | 12:00 Consumer giants and weaker pound against euro push FTSE to record high 16 May 2017 | 11:57 Interventional medicine boost BTG's revenue growth 16 May 2017 | 07:24 BTG revenue at or above upper end of guidance 06 Apr 2017 | 08:28 FLASH: BTG sees significant progress 06 Apr 2017 | 07:07 BTG receives FDA clearance for EKOS 27 Feb 2017 | 13:10

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Mar 2017
31 Mar 2016
Tangible Assets
40.1
35.7
Intangible Assets & Goodwill
904.5
787.1
Investments & Other Non-Current Assets
24.2
28.5
Total Non-Current Assets
968.8
851.3
Inventory
58.4
46.5
Trade & Receivables
125.7
106.5
Cash & Receivables
155.5
140.4
Other Current Assets & Assets Held for Resale
2.7
4.1
Total Assets
1,311.1
1,148.8

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Mar 2017
31 Mar 2016
Short Term Liabilities
165.5
125.0
Long Term Liabilities
165.7
176.1
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
331.2
301.1

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Mar 2017
31 Mar 2016
Net Assets
979.9
847.7

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Mar 2017
31 Mar 2016
Share Capital
38.5
38.3
Minority Interests
0.0
0.0
Retained Earnings
68.4
28.7
Share Premium Account
435.4
434.8
Other Equity
437.6
345.9
Total Equity
979.9
847.7

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Mar 2017
31 Mar 2016
Cashflow from Operating Activities
74.2
95.6
Cashflow Before Financing
28.9
65.7
Increase / Decrease in Cash
9.2
65.7

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Mar 2017
31 Mar 2016
Turnover
570.5
447.5
Cost of Sales
179.9
140.8
Gross Profit
390.6
306.7
Operating Profit
57.5
56.5
Pre-Tax Profit
31.6
57.5
Profit / Loss for the Year
33.6
60.5
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.